Marathon Pharmaceuticals

Share

Marathon Pharmaceuticals

 •  August 30, 2016

— Deflazacort associated with improved muscle strength compared to placebo — — Deflazacort currently undergoing Priority Review by the U.S. FDA — Northbrook, Ill. – August 30, 2016 – Marathon Pharmaceuticals LLC announced the publication of pivotal Phase 3 data evaluating the investigational drug deflazacort for the treatment of Duchenne muscular...

Marathon Pharmaceuticals

 •  August 10, 2016

— FDA approval would allow widespread access for U.S. patients with Duchenne —
— Deflazacort could be among the first FDA-approved treatments for this devastating genetic disorder — Northbrook, Ill. – August 10, 2016 – Marathon Pharmaceuticals, LLC, a biopharmaceutical company developing treatments for rare diseases, today announced the New Drug...

Marathon Pharmaceuticals

 •  March 26, 2016

This week, several representatives from the Marathon team accompanied me to the 2016 MDA Clinical Conference, held in Arlington, Virginia, from Sunday, March 20 through Wednesday, March 23.
The conference brought together nearly 450 neuromuscular disease clinicians, allied health professionals and scientific experts to discuss how to drive the...

Marathon Pharmaceuticals

 •  March 18, 2016

I recently had the opportunity to ask Kurt Harzke, whose son Jacob was diagnosed with Duchenne Muscular Dystrophy (DMD) about ten years ago, how Marathon Pharmaceuticals can best support patients and families affected by the disease. His response: raise awareness, bring better understanding to the general public and keep up our important...

Marathon Pharmaceuticals

 •  March 9, 2016

Patients Can Now Receive Deflazacort, an Investigational Treatment from Marathon, at No Cost Through Medical Research Centers Across U.S.
Marathon Pharmaceuticals, a leader in developing treatments for rare diseases, announced today that it is expanding patient access to deflazacort, its investigational medicine for Duchenne Muscular Dystrophy...

Marathon Pharmaceuticals

 •  December 1, 2015

Patients enrolled in ACCESS DMD™ will receive an investigational drug, deflazacort, at no cost while participating in the program.
Northbrook, Ill. – December 01, 2015 – Marathon Pharmaceuticals, a biopharmaceutical company that develops treatments for rare neurological diseases, today announced that, under the authorization of the U.S. Food and...

Marathon Pharmaceuticals

 •  October 7, 2015

Northbrook, Ill. – October 7, 2015 – Marathon Pharmaceuticals, a biopharmaceutical company that develops new treatments for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for deflazacort, a potential treatment for patients with Duchenne muscular dystrophy (DMD).The rare...

Marathon Pharmaceuticals

 •  September 15, 2015

NORTHBROOOK, Ill., Sept. 15, 2015—Marathon Pharmaceuticals, LLC, a biopharmaceutical company focused on developing treatments for rare neurological and movement disorders, today announced that Dr. Jordan Dubow has joined the company as chief medical officer and vice president of clinical and medical affairs. In his new role, Dr. Dubow will oversee ...

Marathon Pharmaceuticals

 •  September 1, 2015

Marathon Pharmaceuticals, LLC, today announced that a recent publication of a clinical study1 confirmed that ZiNGO® (lidocaine hydrochloride monohydrate, 0.5 mg) powder intradermal injection system significantly reduces venous access pain in pediatric patients. The results were published in the journal Clinical Therapeutics.ZiNGO® is a fast acting ...

Marathon Pharmaceuticals

 •  August 12, 2015

NORTHBROOK, Ill., August 12, 2015 — Marathon Pharmaceuticals, LLC, a biopharmaceutical company focused on developing treatments for rare diseases and neurological disorders, today named Babar Ghias its chief financial officer.In his new role, Ghias will have primary day-to-day responsibility for planning, implementing, managing and controlling all ...